Recent Advancement in Nonsteroidal Aromatase Inhibitors for Treatment of Estrogen-Dependent Breast Cancer
Keywords: (EGFR) HER-2; Aromatase (AR); Aromatase inhibitors; C19 androgenic; COX-2; CYP19; Dual Aromatase-Sulfatase Inhibitors; Estrogen receptor; Estrogen-dependent breast cancer; Estrone 3-sulfamate (EMATE); Isoflavones; Nimesulide Analogues; Nonsteroidal Aromatase Inhibitors; PGE2; YM511; aminoglutethimide; aromatase; aromatase (AR); aromatase inhibitors; breast adipose stromal; celecoxib; cellular transformation; endocrine therapy; flavanone; glycosylated cytochrome P450; granulosa; imidazolic; inflammatory cytokines; inhibitory potency; letrozole, anastrozole; liquiritigenin; long-term tamoxifen treatment; luteal cells; mammary tumors; multienzymatic complex; nonsteroida; nonsteroidal; oncogenesis; ovarian granulosa cells; peripheral tissues; postmenopausal women; prostaglandin E2 (PGE2); prostate cancer; pyridinecontaining (E)-isomer; therapeutic agents; tolerability; traditional Chinese medicine
Document Type: Research Article
Affiliations: Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, 24,Tong Jia Xiang Road, 210009, Nanjing, Jiangsu, P.R. China.
Publication date: 2010-10-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.